AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$ICUI

Sanzone Virginia Ruth sold $819K of ICUI

Sanzone Virginia Ruth (VP, General Counsel) sold 4,856 shares of ICU MEDICAL INC/DE (ICUI) at an average of $168.69 ($167.67–$171.52, $0.82M total) across 4 trades on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sanzone Virginia Ruth
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ICUI
Neutral
medium confidence
Mentioned
$ICUI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

The disclosed sale is modest relative to total shares outstanding, unlikely to move the stock.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential tax planning or diversification; insider may retain significant holdings.

Relevance 4/10Novelty 4/10Timing: 2026‑09‑03 filing

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency for investors.

Company-level read

Ticker impact

$ICUINeutralMedium confidence
Context

VP General Counsel Virginia Ruth Sanzone sold 4,856 shares for $819K via a 10b5‑1 plan on 2026‑09‑03.

Expected impact

Minimal short‑term impact; likely no significant price move.

Evidence & confidence

Form 4 is primary source, but transaction value under $1M limits materiality.

Market effects

Sector

No broader sector impact; typical insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could be unrelated to company outlook; may not indicate negative sentiment.

Key entities

  • Company
    ICU Medical Inc.

    Medical device manufacturer listed on NYSE under ticker ICUI.

  • Insider
    Virginia Ruth Sanzone

    Vice President, General Counsel of ICU Medical.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ICUI insider trading history →

Related articles

AUG 27
$ICUIMed

ICU Medical rating upgraded by S&P on stronger credit metrics

S&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.

investing.com2 min
AUG 14
$ICUIMedAI 8/10

ICU Medical (ICUI) Q2 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.

fool.com7 min
AUG 10
$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ:ICUI) shares rose 10.2% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Adjusted EPS was $2.37 vs $1.91 expected, revenue was $551.7 million vs forecasts, and free cash flow improved to $61.64 million. Full-year adjusted EPS guidance was raised to $8.80 (midpoint).

finance.yahoo.com4 min
AUG 7
$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ: ICUI) shares rose 10.2% after the company reported Q2 adjusted EPS of $2.37, above the $1.91 consensus, and revenue of $551.7 million, above forecasts. Free cash flow improved to $61.64 million from -$8.49 million a year earlier. ICU Medical raised full-year adjusted earnings guidance to $8.80 per share (midpoint).

financialcontent.com3 min
AUG 6
$ICUIMedAI 8/10

ICU Medical (NASDAQ:ICUI) Reports Strong Q2 CY2026

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.

financialcontent.com4 min